Recent findings consolidate the role of Liquid Biopsy in the field of immunotherapy – ESMO
ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
“Management of Advanced Solid Tumours has been a major challenge due to the limited therapeutic strategies available in the past – mainly chemotherapy and radiotherapy.
Recent findings presented at ESMO Immuno24 consolidate the role of Liquid Biopsy in the field of immunotherapy, but prospective research is needed.
Read the analysis by Umberto Malapelle on the ESMO Daily Reporter.”
More posts featuring ESMO.
The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up.
It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.
Umberto Malapelle is an Associate Professor at the School of Medicine at the University of Naples Federico II. He is the Chair of the Predictive Molecular Pathology Laboratory in the Department of Public Health at the same university.
He also serves as the Scientific Secretary of the International Society of Liquid Biopsy and is the Editor-in-Chief of The Journal of Liquid Biopsy. His research focuses on genomic biomarkers for predicting outcomes in lung cancer, colorectal cancer, melanoma, and gastrointestinal stromal tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023